Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, Bin, Zhang, Qi, Ge, Jiwan, Wang, Ruoke, Sun, Jing, Ge, Xiangyang, Yu, Jiazhen, Shan, Sisi +16 more·2020·Nature
DOI 10.1038/s41586-020-2380-z

Cited by (1,008)

Items 901–1,000 of 1,008

  1. The Importance of Glycosylation in COVID-19 Infection
    Tea Pribić, Gordan Lauc, Irena Trbojević‐Akmačić · 2021 · Advances in experimental medicine and biology
  2. Angiotensin-converting enzyme 2 in peripheral lung club cells modulates the susceptibility to SARS-CoV-2 in chronic obstructive pulmonary disease
    Yang Peng, Zhao-Ni Wang, Shi-Ying Chen, Ai-Ru Xu, Zhangfu Fang, Jing Sun, Ziqing Zhou, Xiaotao Hou, Lai‐jian Cen, Jianjuan Ma et al. · 2022 · American Journal of Physiology-Lung Cellular and Molecular Physiology
  3. Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allostery as Energetic Drivers of Highly Transmissible Spike Variants
    Gennady M. Verkhivker, Steve Agajanian, Ryan Kassab, Keerthi Krishnan · 2022 · Journal of Chemical Information and Modeling
  4. Comparison of Six Serological Immunoassays for the Detection of SARS-CoV-2 Neutralizing Antibody Levels in the Vaccinated Population
    Hee-Jung Lee, Jin Jung, Ji Hyun Lee, Dong-Gun Lee, Y. B. Kim, E. Oh · 2022 · Viruses
  5. Neutralizing and enhancing antibodies against SARS-CoV-2
    Yafei Liu, Hisashi Arase · 2022 · Inflammation and Regeneration
  6. Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
    Hung Van Nguyen, Hoang Linh Nguyen, Pham Dang Lan, Nguyen Quoc Thai, Mateusz Sikora, Mai Suan Li · 2023 · Chemical Society Reviews
  7. Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection
    Ruoke Wang, Yang Han, Rui Zhang, Jiayi Zhu, Xuanyu Nan, Yaping Liu, Ziqing Yang, Bini Zhou, Jinfang Yu, Zichun Lin et al. · 2023 · Immunity
  8. Isolation and characterization of mpox virus from the first mpox case in Shenzhen, China
    Lin Cheng, Liuqing Yang, Miao Wang, Yabo Peng, Haiyan Wang, Xiaoxiang Yang, Juanjuan Zhao, Mingxia Zhang, Fuxiang Wang, Zheng Zhang · 2024 · Virologica Sinica
  9. A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response
    Woong Kim, Eun Su Song, Song Ha Lee, Seung Ho Yang, Junhyung Cho, Seok‐Jun Kim · 2024 · Scientific Reports
  10. Deep mutational learning for the selection of therapeutic antibodies resistant to the evolution of Omicron variants of SARS-CoV-2
    Lester Frei, Beichen Gao, Jiami Han, Joseph M. Taft, Edward B. Irvine, Cédric R. Weber, Rachita K. Kumar, Benedikt N. Eisinger, Andrey Ignatov, Zaibo Yang et al. · 2025 · Nature Biomedical Engineering
  11. Serum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patients
    Meijuan Zheng, Yong Gao, Siyu Liu, Dandan Sun, Fan Yang, Lu Zong, Min Zhang, Zhigang Tian, Yuanhong Xu, Haoyu Sun · 2020 · Cellular and Molecular Immunology
  12. The development of neutralizing antibodies against SARS-CoV-2 and their common features
    Liu Daisy Liu, Chaoyang Lian, Leng-Siew Yeap, Fei‐Long Meng · 2020 · Journal of Molecular Cell Biology
  13. A peptide-based assay discriminates individual antibody response to SARS-CoV-2
    Immacolata Polvere, Serena Voccola, Gaetano Cardinale, Maurizio Fumi, Francesca Aquila, Alfredina Parrella, Jessica Raffaella Madera, Romania Stilo, Pasquale Vito, Tiziana Zotti · 2021 · Genes & Diseases
  14. Possible COVID-19 reinfection in a patient with X-linked agammaglobulinaemia
    Sook Yin Loh, John K. Bassett, Emily Hoodless, Martin John Walshaw · 2021 · BMJ Case Reports
  15. Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction
    X. Qiang, Shu Zhu, Jian-Hua Li, Weiqiang Chen, Huan Yang, Ping Wang, K. Tracey, Haichao Wang · 2021 · Journal of Leukocyte Biology
  16. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine
    Xingdong Zhou, Hui Wang, Qun Ji, Mingjuan Du, Yuexia Liang, Huanhuan Li, Fan Li, Hang Shang, Xiujuan Zhu, Wei Wang et al. · 2021 · Protein & Cell
  17. In-silico immunoinformatic analysis of SARS-CoV-2 virus for the development of putative vaccine construct
    Abhishek Sharma, Surinder Pal, Anil Panwar, Suresh Kumar, Ashok Kumar · 2021 · Immunobiology
  18. Drug repositioning against COVID-19: a first line treatment
    Nousheen Bibi, Ayesha Farid, Sana Gul, Johar Ali, Farhat Amin, Umesh Kalathiya, Ted R. Hupp · 2021 · Journal of Biomolecular Structure and Dynamics
  19. Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes
    Zhaohui Qian, Pei Li, Xiaolu Tang, Jian Lü · 2022 · Medical Review
  20. The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition
    Shuyuan Qiao, Shuyuan Zhang, Jiwan Ge, Xinquan Wang · 2022 · FEBS Open Bio
  21. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses
    Joseph Torresi, Melissa Anne Edeling, Terry M. Nolan, Dale Ian Godfrey · 2022 · Frontiers in Immunology
  22. Molecular Mechanism of the Non-Covalent Orally Targeted SARS-CoV-2 Mpro Inhibitor S-217622 and Computational Assessment of Its Effectiveness against Mainstream Variants
    Danyang Xiong, Xiaoyu Zhao, Song Luo, John Z. H. Zhang, Lili Duan · 2022 · The Journal of Physical Chemistry Letters
  23. Recent Approaches to mRNA Vaccine Delivery By Lipid-Based Vectors Prepared By Continuous-Flow Microfluidic Devices
    Mahtab Ghasemi Toudeshkchouei, Atefeh Tavakoli, Hossein Mohammadghasemi, Anita Karimi, Jafar Ai, Mohammad Rabiee, Navid Rabiee · 2022 · Future Medicinal Chemistry
  24. Impact of BA.1, BA.2, and BA.4/BA.5 Omicron Mutations on Therapeutic Monoclonal Antibodies
    Bahaa Jawad, Puja Adhikari, Rudolf Podgornik, W. Y. Ching · 2022 · Computers in Biology and Medicine
  25. Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies
    Rachael E. Whaley, Sarah Ameny, Tanvi Arkatkar, Aaron M. Seese, Abigail Wall, Iram Khan, Joseph J. Carter, Erin M. Scherer, David J. Rawlings, Denise A. Galloway et al. · 2020 · Journal of Immunological Methods
  26. Identifying key determinants and dynamics of SARS-CoV-2/ACE2 tight interaction
    Van A. Ngo, Ramesh K. Jha · 2021 · PLoS ONE
  27. Ultrasensitive Detection of SARS-CoV-2 Spike Proteins Using the Thio-NAD Cycling Reaction: A Preliminary Study before Clinical Trials
    Yuta Kyosei, Mayuri Namba, Daiki Makioka, Ayumi Kokubun, Satoshi Watabe, Teruki Yoshimura, Tadahiro Sasaki, Tatsuo Shioda, Etsuro Ito · 2021 · Microorganisms
  28. SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage
    Ruoke Wang, Qi Zhang, Jiwan Ge, Wenlin Ren, Rui Zhang, Jun Lan, Bin Ju, Bin Su, Fengting Yu, Peng Chen et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  29. Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines
    Mohammad Reza Sepand, Banafsheh Bigdelou, Jim Q. Ho, Mohammad Sharaf, Alexis J. Lannigan, Ian M. Sullivan, Alecsander P. da Silva, Leland O. Barrett, Scott McGoldrick, Yuvraj Lnu et al. · 2022 · Antibodies
  30. Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19
    Natalie M. Kirk, Yu-Ying Liang, H. Ly · 2024 · Virulence
  31. Tapered chiral nanoparticles as broad-spectrum thermally stable antivirals for SARS-CoV-2 variants
    Rui Gao, Xinxin Xu, Prashant Kumar, Ye Liu, Hongyu Zhang, Xiao Lei Guo, Maozhong Sun, Felippe Mariano Colombari, André Farias de Moura, Changlong Hao et al. · 2024 · Proceedings of the National Academy of Sciences
  32. SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development
    Àlex Olvera, Marc Noguera-Julián, Athina Kilpeläinen, Luis Romero-Martín, Júlia G. Prado, Christian Brander · 2020 · Vaccines
  33. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control
    Shamala Salvamani, HZ Tan, WJ Thang, HC Ter, MS Wan, Baskaran Gunasekaran, Anthony Rhodes · 2020 · British Journal of Biomedical Science
  34. Review of pharmacologic and immunologic agents in the management of COVID-19
    Marzuq A. Ungogo, Mustapha Mohammed, Bala Ningi Umar, Auwal Adam Bala, Garba M. Khalid · 2021 · Biosafety and Health
  35. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19
    Junsen Chen, Rui Huang, Yiwen Nie, Xinyue Wen, Ying Wu · 2020 · Virologica Sinica
  36. Persistent positivity of SARS-CoV-2 nucleic acid in asymptomatic healthcare worker: infective virion or inactive nucleic acid?
    Lokesh Kumar Tiwari, Prakriti Gupta, Chandra Mani Singh, Prabhat Kumar Singh · 2021 · BMJ Case Reports
  37. COVID-19 vaccines: Global challenges and prospects forum recommendations
    Mohamed Boudjelal, Faisal Almajed, Ahmed M. Salman, Naif Khalaf Alharbi, Margaretta Colangelo, Julia M. Michelotti, Gene G. Olinger, Mariwan Baker, Adrian V. S. Hill, Ahmed S. Alaskar · 2021 · International Journal of Infectious Diseases
  38. Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling.
    Neda K. Dezfuli, Ian Michael Adcock, Nooshin Montazami, Esmaeil Mortaz, Ali Akbar Velayati · 2020 · PubMed Central
  39. Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrate the Functional Importance of the Receptor Binding Domain
    G. Mantus, Lindsay E. Nyhoff, Robert C Kauffman, V. Edara, Li-Lin Lai, K. Floyd, Pei-Yong Shi, V. Menachery, S. Edupuganti, E. Scherer et al. · 2021 · Journal of Immunology
  40. Rational optimization of a human neutralizing antibody of SARS-CoV-2
    Jiao Chen, Fei Wu, Lin Dan, Weikang Kong, Xueting Cai, Jie Yang, Xiaoyan Sun, Peng Cao · 2021 · Computers in Biology and Medicine
  41. Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants
    Hua Xu, Bo Wang, Tian-Ning Zhao, Ziteng Liang, Tianbo Peng, Xiaohui Song, Jiajing Wu, Youchun Wang, Xiao‐Dong Su · 2021 · Cell Research
  42. Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination
    Pratik Datta, Rahul Ukey, Natalie Bruiners, William J. Honnen, Mary O. Carayannopoulos, Charles Reichman, Alok Kumar Choudhary, Alberta Onyuka, Deborah Handler, Valentina Guerrini et al. · 2021 · Journal of Immunological Methods
  43. Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody
    Shuai Yue, Zhirong Li, Yao Lin, Yang Yang, Mengqi Yuan, Zhiwei Pan, Hu Li, Leiqiong Gao, Jing Zhou, Jianfang Tang et al. · 2021 · Frontiers in Immunology
  44. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency
    Sabrina Mariotti, Antonio Capocefalo, Maria Vincenza Chiantore, Angelo Iacobino, Raffaela Teloni, Maria Laura De Angelis, Alessandra Gallinaro, Maria Franca Pirillo, Martina Borghi, Andrea Canitano et al. · 2021 · Frontiers in Immunology
  45. ZnO Nanowire‐Based Early Detection of SARS‐CoV‐2 Antibody Responses in Asymptomatic Patients with COVID‐19
    Jung Kim, Sung Kyun Lee, Jonghwan Lee, Hye‐Yeon Kim, Nam Hoon Kim, Chang Hoon Lee, Chang‐Seop Lee, Hong Gi Kim · 2022 · Advanced Materials Interfaces
  46. Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models
    Young-Il Kim, Mark Anthony B. Casel, Young-Ki Choi · 2022 · Journal of Microbiology
  47. Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: a dynamic insight
    Xiaoyu Zhao, Danyang Xiong, Song Luo, Lili Duan · 2022 · Physical Chemistry Chemical Physics
  48. Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection
    Song Mu, Shuyi Song, Yanan Hao, Feiyang Luo, Rui‐Xin Wu, Yi Wang, Xiaojian Han, Tingting Li, Chao Hu, Shenglong Li et al. · 2022 · Frontiers in Medicine
  49. A Four-Channel Surface Plasmon Resonance Sensor Functionalized Online for Simultaneous Detections of Anti-SARS-CoV-2 Antibody, Free Viral Particles, and Neutralized Viral Particles
    Tianbao Dong, Chaowei Han, Meng Jiang, Tiantian Zhang, Qing Kang, Pengcheng Wang, Feimeng Zhou · 2022 · ACS Sensors
  50. CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and Omicron, and inhibits viral infection
    Zongzhi Z. Liu, Xiang Gao, Chuanwen Kan, Lingyu Li, Yuan Zhang, Yibo Gao, Shengyuan Zhang, Liangji Zhou, Hui Zhao, Mingkun Li et al. · 2023 · MedComm
  51. Current knowledge of COVID-19: Advances, challenges and future perspectives
    Yuhan Wu, Zhuobing Peng, Yongxue Yan, Jintao Hu, Yalong Wang, Xiaoyu Wang, Ruchao Peng, Daniel Watterson, Yi Shi · 2021 · Biosafety and Health
  52. Epitope mapping of neutralising anti‐SARS‐CoV‐2 monoclonal antibodies: Implications for immunotherapy and vaccine design
    Somayeh Ghotloo, Faezeh Maghsood, Forough Golsaz‐Shirazi, Mohammad Mehdi Amiri, Christiane Moog, Fazel Shokri · 2022 · Reviews in Medical Virology
  53. Structural basis of fitness of emerging SARS-COV-2 variants and considerations for screening, testing and surveillance strategy to contain their threat
    Sk Ramiz Islam, Debasish Prusty, Soumen Kanti Manna · 2021 · medRxiv
  54. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant viruses is up to 10-fold reduced
    Xinyue Chang, Gilles Sousa Augusto, Xuelan Liu, Thomas M. Kündig, Monique Vogel, Mona Omar Mohsen, Martin F. Bachmann · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  55. Omicron BA.2 specifically evades broad sarbecovirus neutralizing antibodies
    Yunlong Cao, Ayijiang Yisimayi, Fanchong Jian, Tianhe Xiao, Weiliang Song, Jing Wang, Shuo Du, Zhiying Zhang, Pulan Liu, Xiaohua Hao et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  56. Humanity tested
    2020 · Nature Biomedical Engineering
  57. Human antibodies can neutralize SARS-CoV-2
    Jovani Catalan‐Dibene · 2020 · Nature reviews. Immunology
  58. Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives
    T. Koma, Shun Adachi, Naoya Doi, A. Adachi, Masako Nomaguchi · 2020 · Frontiers in Microbiology
  59. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
    Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli · 2022 · Pharmacological Reviews
  60. Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain
    C. Patrick, V. Upadhyay, Alexandra Lucas, Krishna M. G. Mallela · 2022 · bioRxiv
  61. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
    Laura Radić, Kwinten Sliepen, Victor C. Yin, Mitch Brinkkemper, Joan Capella-Pujol, A. Schriek, J. Torres, S. Bangaru, J. Burger, M. Poniman et al. · 2022 · bioRxiv
  62. Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD
    Hui Sun, Tingting Deng, Yali Zhang, Yanling Lin, Yanan Jiang, Yichao Jiang, Yang Huang, Shuo Song, Lingyan Cui, Tingting Li et al. · 2023 · Protein & Cell
  63. Emerging Trends of Gold Nanostructures for Point-of-Care Biosensor-Based Detection of COVID-19
    Akhilesh Kumar Yadav, Nagaraj Basavegowda, Saba Shirin, Shiji Raju, Rajkumar Sekar, Prathap Somu, Uluvangada Thammaiah Uthappa, Gholamreza Abdi · 2024 · Molecular Biotechnology
  64. Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019
    Wenyi Peng, Hao Wu, Yan Lin Tan, Mei Li, Dachun Yang, Shuang Li · 2020 · Life Sciences
  65. Severe Acute Respiratory Syndrome Coronavirus-2 Infections in Critical Care Staff: Beware the Risks Beyond the Bedside
    Kate El Bouzidi, Tasneem Pirani, Carolina Rosadas, Samreen Ijaz, Matthew Pearn, Shehnila Chaudhry, Sameer Patel, Macià Sureda-Vives, Natalia Fernández, Maryam Khan et al. · 2021 · Critical Care Medicine
  66. Reinfection or Reactivation of Coronavirus-19 in Patients with Hematologic Malignancies: Case Report Series
    Rajan Kapoor, Ranjith K. Nair, Neelabh Nayan, Sharad Bhalla, Jasdeep Singh · 2021 · SN Comprehensive Clinical Medicine
  67. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach
    Alexander Kwarteng, Ebenezer Asiedu, Augustina Angelina Sylverken, Amma Aboagyewa Larbi, Samuel Asamoah Sakyi, Samuel Opoku Asiedu · 2021 · Infection Genetics and Evolution
  68. Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants
    Yuanyuan Qu, Xueyan Zhang, Meiyu Wang, Lina Sun, Yongzhong Jiang, Cheng Li, Wei Wu, Zhen Chen, Qiangling Yin, Xiaolin Jiang et al. · 2021 · Virologica Sinica
  69. Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2
    Larissa Rodrigues Gomes, Andressa M. Durans, Paloma Napoleão-Pêgo, Jessica A. Waterman, Mariana S. Freitas, Nathalia Beatriz Ramos de Sá, Lilian V. Pereira, Jéssica S. Furtado, Romário G. Aquino, Mario C. R. Machado et al. · 2021 · Vaccines
  70. Immune response variables and viral mutations impact on COVID-19 reinfection and relapse
    Sarvin Sanaie, Elham Golipour, Ali Shamekh, Mohammad Reza Sadaie, Ata Mahmoodpoor, Mehdi Yousefi · 2021 · International Immunopharmacology
  71. An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
    Nathaniel L. Miller, Thomas Clark, Rahul Raman, Ram Sasisekharan · 2021 · Viruses
  72. Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies
    Tal Noy-Porat, Avishay Edri, Ron Alcalay, Efi Makdasi, David Gur, Moshe Aftalion, Yentl Evgy, Adi Beth-Din, Yinon Levy, Eyal Epstein et al. · 2021 · Antibodies
  73. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy
    Dongyan Zhou, Run-Hong Zhou, Zhi-Wei Chen · 2021 · Immunotherapy Advances
  74. Combined Prospective Seroconversion and PCR Data of Selected Cohorts Indicate a High Rate of Subclinical SARS-CoV-2 Infections—an Open Observational Study in Lower Saxony, Germany
    Rebecca Jonczyk, Nils Stanislawski, Lisa K. Seiler, Holger Blume, Stefanie Heiden, Henning Lucas, Samir Sarikouch, Philipp‐Cornelius Pott, Meike Stiesch, Corinna Hauß et al. · 2022 · Microbiology Spectrum
  75. Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization
    Huimin Guo, Qing Fan, Shuo Song, Senlin Shen, Bing Zhou, Haiyan Wang, Lin Cheng, Xiangyang Ge, Bin Ju, Zheng Zhang · 2022 · Journal of Clinical Virology
  76. Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2
    Hong-Su Park, Y. Matsuoka, Cindy Luongo, Li-Juan Yang, Celia Santos, Xue-Qiao Liu, Laura R. H. Ahlers, Ian N. Moore, Sharmin Afroz, Reed F. Johnson et al. · 2022 · npj Vaccines
  77. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals
    Armel Landry Batchi-Bouyou, Jean Claude Djontu, Jeannhey Christevy Vouvoungui, Claujens Chastel Mfoutou Mapanguy, Line Lobaloba Ingoba, Jiré Séphora Mougany, Reauchelvy Kamal Boumpoutou, Steve Diafouka-Kietela, Raoul Ampa, Francine Ntoumi · 2022 · BMC Infectious Diseases
  78. Targeting the Receptor-Binding Motif of SARS-CoV-2 with D-Peptides Mimicking the ACE2 Binding Helix: Lessons for Inhibiting Omicron and Future Variants of Concern
    Pedro Alberto Valiente, Satra Nim, JinAh Lee, Seungtaek Kim, Philip M. Kim · 2022 · Journal of Chemical Information and Modeling
  79. A Cell-Based ELISA to Improve the Serological Analysis of Anti-SARS-CoV-2 IgG
    Zarletti Gianpaolo, Massimo Tiberi, Veronica De Molfetta, Maurizio Bossù, Elisa Toppi, Paola Bossù, Giuseppe Scapigliati · 2020 · Viruses
  80. Therapeutic approaches against coronaviruses acute respiratory syndrome
    Camilla Servidio, Francesco Stellacci · 2020 · Pharmacology Research & Perspectives
  81. Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents
    Jacek Plichta, Piotr Kuna, Michał Panek · 2022 · COVID
  82. SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys
    Kevin O. Saunders, Esther Lee, Robert Parks, David R. Martinez, Dapeng Li, Haiyan Chen, Robert J. Edwards, S. Gobeil, Maggie Barr, Katayoun Mansouri et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  83. A high-throughput, automated, cell-free expression and screening platform for antibody discovery
    Andrew C. Hunt, Bastian Vögeli, Weston Kightlinger, Danielle J. Yoesep, Antje Krüger, Michael C. Jewett · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  84. Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
    Lihong Liu, Ryan G. Casner, Yicheng Guo, Qian Wang, Sho Iketani, Jasper Fuk‐Woo Chan, Jian Yu, Bernadeta Dadonaite, Manoj S. Nair, Hiroshi Mohri et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  85. A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients
    Deanna J. Buehrle, Robert R. Sutton, Erin L. McCann, AARON E. LUCAS · 2021 · Viruses
  86. Analysis of BNT162b2‐ and CVnCoV‐elicited sera and of convalescent sera toward SARS‐CoV‐2 viruses
    Sascha Hein, Marie‐Luise Herrlein, Ines Mhedhbi, Daniela Bender, Vanessa Haberger, Nuka Ivalu Benz, Jonathan Eisert, Julia Stingl, Michael Dreher, Doris Oberle et al. · 2021 · Allergy
  87. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern
    Blanca J. Valdovinos-Navarro, Salvador Dueñas, Gonzalo Isaí Flores-Acosta, Jahaziel Gasperin-Bulbarela, Johanna Bernáldez-Sarabia, Olivia Cabanillas-Bernal, Karla Cervantes-Luévano, Alexei F. Licea-Navarro · 2022 · International Journal of Molecular Sciences
  88. Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted
    Delphine Diana Acar, Wojciech Witkowski, Magdalena Wejda, Ruifang Wei, Tim Desmet, Bert Schepens, Sieglinde De Cae, Koen Sedeyn, Hannah Eeckhaut, Daria Fijałkowska et al. · 2024 · EBioMedicine
  89. An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spike
    Banghui Liu, Xuefeng Niu, Yijun Deng, Zhaoyong Zhang, Yanqun Wang, Xijie Gao, Huan Liang, Zimu Li, Qian Wang, Yuanyi Cheng et al. · 2024 · Cell Reports
  90. The challenges and breakthroughs in the development of diagnostic monoclonal antibodies
    Jing Wang, Qitao Song, Tao Yang, Yuanli Li, Lihua Zhang, Jiayan Li, Fei‐Fei Liu, Yanyin Lin, Xiaoxia Xu, Heng Yu et al. · 2024 · Open Research (University of Surrey)
  91. Enabling the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants including KP.2
    Chao Su, Juanhua He, Yufeng Xie, Yu Hu, Xin Li, Shitong Qiao, Peipei Liu, Min Huang, Rong Zhang, Liang Wang et al. · 2025 · hLife
  92. SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics
    Nadia Siles, Maisey Schuler, Cole P. Maguire, Dzifa Amengor, Annalee W. Nguyen, Rebecca E Wilen, Jacob E. Rogers, Sam A. Bazzi, Blaine Caslin, Christopher DiPasquale et al. · 2025 · Communications Medicine
  93. Adaptive immunity to SARS-CoV-2
    D. Altmann · 2020 · Oxford Open Immunology
  94. Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19
    Yang Han, Peipei Liu, Yang Qiu, Jie Zhou, Ying Liu, Xujuan Hu, Qingyu Yang, Rui Huang, Xinyue Wen, Hao Song et al. · 2021 · JCI Insight
  95. Could Antigen Presenting Cells Represent a Protective Element during SARS-CoV-2 Infection in Children?
    Rita Lauro, Natasha Irrera, Ali Hussein Eid, Alessandra Bitto · 2021 · Pathogens
  96. SARS‐CoV‐2 antibodies: Comparison of three high‐throughput immunoassays versus the neutralization test
    Riccardo Laterza, Annalisa Schirinzi, Rossella Bruno, Rosa Genco, Renato Contino, Angelo Ostuni, Francesca Di Serio · 2021 · European Journal of Clinical Investigation
  97. Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms
    Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · ACS Omega
  98. Decreased Long‐Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019
    Aránzazu Caballero‐Marcos, María Jesús Citores, Roberto Alonso, Manuel Rodríguez‐Perálvarez, Maricela Valerio, Javier Graus Morales, Valentín Cuervas‐Mons, Alba Cachero, Carmelo Loinaz, Mercedes Iñarrairaegui et al. · 2021 · Liver Transplantation
  99. Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein
    Carlos Costa, Arménio Jorge Moura Barbosa, Ana Margarida Gonçalves Carvalho Dias, Ana Cecília A. Roque · 2022 · Biotechnology Advances
  100. Comparison of the humoral and cellular immunity in COVID-19 convalescents
    А. П. Топтыгина, Elena L. Semikina, Закиров Рустам Шакирович, Zulfiia E. Afridonova · 2022 · Russian Journal of Infection and Immunity